Related Topics News -

     
 Detail   |   Print 
     
《大行》中金指藥明生物盈利能力改善 升目標價25%至60元兼上調盈測
2026-08-28T  
《大行》招銀國際升藥明生物目標價至60元 維持「買入」評級
2026-08-28T  
《大行》美銀證券升藥明生物目標價至56元 積壓訂單增長
2026-08-27T  
《大行》里昂升藥明生物目標價至65.7元 管理層上調收入指引
2026-08-27T  
《大行》大和:藥明生物上半年業績受惠毛利率優於預期 升目標價至59元
2026-08-27T  
《大行》高盛升藥明生物目標價至49元 上半年收入及盈利勝預期
2026-08-27T  
《大行》花旗升藥明生物目標價至62元 評級「買入」
2026-08-27T  
傳藥明康德出售藥明合聯2.6%股權 最高作價24億元
2026-08-27T  
《大行》野村升藥明生物目標價至60.22元 上半年業績勝預期
2026-08-26T  
《大行》大摩升藥明生物目標價至57元 上半年業績勝預期
2026-08-26T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.